Form 4: Sutro Biopharma Executive Linda Fitzpatrick Reports Stock Transactions

Linda Fitzpatrick, Chief People & Communications Officer at Sutro Biopharma, reports the vesting and tax withholding of restricted stock units.

Summary

• Linda Fitzpatrick, Chief People & Communications Officer of Sutro Biopharma, filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2025, 9,125 shares of common stock were acquired through the vesting of restricted stock units (RSUs).
• Also on March 4, 2025, 3,748 shares were withheld by the issuer to satisfy income tax obligations related to the RSU settlement at a price of $1.42.
• Following these transactions, Fitzpatrick directly owns 90,277 shares of common stock.
• Additionally, 10,383 shares are held indirectly through the Michael A. & Linda A. Fitzpatrick Family Trust dated 10/13/1997.
• Fitzpatrick also holds 9,125 derivative securities in the form of Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard compensation practices; it doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation.

Key Dates